Beximco Pharmaceuticals Limited (“BPL”, “Beximco Pharma” or “Company”) has commenced export of medicines to Kuwait, a press release says today.
This is the first time a Bangladeshi pharmaceutical company has launched pharmaceutical products in any gulf member country (GCC). A launching ceremony was held at the factory 
premises of Beximco Pharma to mark the shipment of first consignment to Kuwait in presence of the ambassador of Kuwait His Excellency Mr. Adel Mohammad A. H Hayat. Vice Chairman of Beximco group Mr. Salman F Rahman, Beximco Pharma’s Managing Director Mr. Nazmul Hassan, MP, Chief operating Officer Mr. Rabbur Reza and other high officials of the company were also present on this occasion.
The ambassador has also seen the operations of various units at Tongi factory and expressed high satisfaction over the state-of-the-art facilities and quality control practices of Beximco Pharma. He expressed keen interest in Beximco medicines and hoped for substantial import from the company in the near future.
Initially two metered dose inhaler products for asthma and respiratory disorders namely Azmasol (Salbutamol) and Bexitrol-F (Salmeterol plus Fluticasone) and one blood pressure drug Amdocal (Amlodipine) are being exported to Kuwait. The Company expects to launch additional products in Kuwait later this year. Total pharma market of the Gulf Cooperation Council (GCC), consisting of six Arab nations, is currently valued at around $9 billion and Kuwait has a pharma market worth about a billion dollar.
Answering to the questions from journalists Salman F Rahman said “Beximco pharma is exporting medicine to 54 countries including Kuwait. Beximco Pharma had worked hard for the last seven years to get necessary approvals from the authority which are normally a lengthy process as well. Now we are expecting to export 1 billion dollar within next five years which was 15 million dollar las year.”
On this occasion, the Managing Director of Beximco Pharma, Nazmul Hassan MP, said: “Beximco Pharma is building its presence in many emerging and developed markets. The Company is increasingly focused on regulated markets such as the US, EU, GCC and Australia where the demand for generic products is rising. Gulf or GCC is an important market for us and the launch of products in Kuwait will open up new business opportunities for the company. We will continue to expand our product basket for the gulf region aiming to provide patients with safe and affordable treatment options.”
About Beximco Pharma:
Beximco Pharma is the largest exporter of pharmaceuticals in Bangladesh, winning the National Export Trophy (Gold), the highest national accolade for export, a record five (05) times. The Company currently has a global footprint in more than 50 countries and its manufacturing facilities are accredited by the major global regulatory authorities namely US FDA, AGES (EU), TGA (Australia), Health Canada, GCC (Gulf), TFDA (Taiwan) etc.
